NervGen Pharma Corp. announced the resignation of Chief Financial Officer William J. Adams effective March 15, 2026, due to retirement, with transitional services through June 15, 2026. The Board appointed Dr. Adam Rogers as interim Chief Financial Officer and Principal Financial and Accounting Officer effective the same date.
Key takeaways
William J. Adams resigned as CFO, Secretary, and Principal Financial and Accounting Officer effective March 15, 2026, due to retirement.
No disagreements with management or Board prompted Adams' resignation.
Adams to provide transitional services through June 15, 2026, at one-third base salary.
Adams entitled to extension of vested stock awards expiration.
Dr. Adam Rogers appointed interim CFO and Principal Financial and Accounting Officer effective March 15, 2026.